This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Founded in 1994 and headquartered in Denver, CO, DaVita Inc. is a leading provider of dialysis services in the U.S. to patients suffering from chronic kidney failure, also known as end stage renal disease (ESRD). The company operates kidney dialysis centers and provides related medical services primarily in dialysis centers and in contracted hospitals across the U.S. Its services include outpatient dialysis services, hospital inpatient dialysis services and ancillary services such as ESRD laboratory services and disease management services.
Can BD Medical Drive Becton, Dickinson's (BDX) Q3 Earnings?
by Zacks Equity Research
Becton, Dickinson (BDX) expects to gain from core segmental strength in the third quarter.
Cigna (CI) to Report Q2 Earnings: What's in the Offing?
by Zacks Equity Research
Cigna's (CI) Q2 earnings should reflect increase in revenues from growth across its segments and share buyback.
Is a Beat in the Cards for Humana's (HUM) Earnings in Q2?
by Zacks Equity Research
Humana's (HUM) second-quarter earnings are likely to gain traction from a solid revenue stream.
What's in the Cards for DaVita (DVA) This Earnings Season?
by Zacks Equity Research
DaVita (DVA) projects operating income within $460-$465 million for the second quarter.
Top Ranked Momentum Stocks to Buy for July 26th
by Zacks Equity Research
Here are four stocks with buy rank and strong momentum characteristics for investors to consider today, July 26th
DaVita HealthCare (DVA) Earnings Expected to Grow: Should You Buy?
by Zacks Equity Research
DaVita HealthCare (DVA) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
DVA vs. CHE: Which Stock Is the Better Value Option?
by Zacks Equity Research
DVA vs. CHE: Which Stock Is the Better Value Option?
New Strong Buy Stocks for July 25th
by Tirthankar Chakraborty
Here are 5 stocks added to the Zacks Rank #1 (Strong Buy) List for Thursday
Stock Market News For Jul 23, 2019
by Zacks Equity Research
Markets ended in the green on Monday following a broad-based rally in the tech stocks.
DaVita (DVA) Announces Preliminary Q2 Results, View Upbeat
by Zacks Equity Research
Management at DaVita (DVA) expects impressive contribution from calcimimetics in Q2.
UnitedHealth (UNH) Beats on Q2 Earnings, Guides Up for 2019
by Zacks Equity Research
Strong segment performance, membership growth and cost control aid UnitedHealth's (UNH) Q2 results.
UnitedHealth (UNH) to Report Q2 Earnings: What's in Store?
by Zacks Equity Research
UnitedHealth's (UNH) second-quarter results are expected to be boosted by the revenue growth at UnitedHealthcare and Optum segments and increasing membership.
The Zacks Analyst Blog Highlights: DaVita, Fresenius, Baxter, Amgen and CVS
by Zacks Equity Research
The Zacks Analyst Blog Highlights: DaVita, Fresenius, Baxter, Amgen and CVS
Trump's Order on Kidney Care Lifts These Dialysis Stocks
by Tirthankar Chakraborty
Dialysis stocks move north after Trump signs an executive order designed to reform the nation's kidney treatment industry.
Trump's Kidney Disease Executive Order May Boost This Health Stock, Tank Others
by Mitchell Moore
President Trump signed an executive order Wednesday that will encourage an increase in kidney transplants. This transplant diagnostic company stands to grow significantly, while dialysis companies will take a hit.
UnitedHealth (UNH) Closes DaVita Unit Buy, Expands OptumCare
by Zacks Equity Research
UnitedHealth's (UNH) purchase of DaVita Medical Group will likely aid the growth of OptumHealth, which is targeting double-digit percentage revenue long-term growth.
DaVita Divests DMG to Optum, Boosts Kidney Care Services
by Zacks Equity Research
The divestment of DMG boosts DaVita's (DVA) core Kidney Care business.
Why Is DaVita HealthCare (DVA) Down 9.9% Since Last Earnings Report?
by Zacks Equity Research
DaVita HealthCare (DVA) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Here's Why You Should Retain DaVita (DVA) in Your Portfolio
by Zacks Equity Research
DaVita (DVA) is gaining steadily from expansion in international markets, strong demand in dialysis services and prudent acquisitions. However, divestment of DMG segment might lower cash flows.
DaVita (DVA) Earnings and Revenues Miss Estimates in Q1
by Zacks Equity Research
DaVita (DVA) gains from international revenues in Q1.
DaVita HealthCare (DVA) Q1 Earnings and Revenues Miss Estimates
by Zacks Equity Research
DaVita HealthCare (DVA) delivered earnings and revenue surprises of -4.21% and -2.74%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?
What's in the Cards for DaVita (DVA) This Earnings Season?
by Zacks Equity Research
Better-than-expected performance at Kidney Care, strategic buyouts and international expansion might aid DaVita (DVA) in Q1. However, integration risks might be a dampener.
Analysts Estimate DaVita HealthCare (DVA) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
DaVita HealthCare (DVA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Analysts Estimate DaVita HealthCare (DVA) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
DaVita HealthCare (DVA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Here's Why You Should Hold on to DaVita (DVA) Stock Now
by Zacks Equity Research
DaVita (DVA) is gaining steadily from expansion in international markets, strong demand in dialysis services and prudent acquisitions. However, rising expenses remain a dampener.